Contracts › 75F40123F19026
75F40123F19026: Endorsement Iii: Promotion of Prescription Drugs in Native Advertising
Awarded to Westat, Inc. by Food and Drug Administration (FDA).
$582Kobligated
$582Kpotential value
31 August 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40123F19026 |
|---|---|
| Vehicle | 75F40120A00018 |
| Awardee | Westat, Inc. |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541820 Public Relations Agencies |
| PSC | B599 Special Studies/Analysis- Other |
| Place of performance | MD |
| Period of performance | 01 September 2023 to 31 August 2027 |
| Potential end | 31 August 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541820 contracts · All expiring contracts · USASpending record